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Abstract
Background: The strenuous procurement of cultured human hepatocytes and their short lives have constrained
the cell culture model of cytochrome P450 (CYP450) induction, xenobiotic biotransformation, and hepatotoxicity.
The development of continuous non-tumorous cell line steadily containing hepatocyte phenotypes would
substitute the primary hepatocytes for these studies.
Results: The hepatocyte-like cells have been developed from hTERT plus Bmi-1-immortalized human mesenchymal
stem cells to substitute the primary hepatocytes. The hepatocyte-like cells had polygonal morphology and steadily
produced albumin, glycogen, urea and UGT1A1 beyond 6 months while maintaining proliferative capacity.
Although these hepatocyte-like cells had low basal expression of CYP450 isotypes, their expressions could be
extensively up regulated to 80 folds upon the exposure to enzyme inducers. Their inducibility outperformed the
classical HepG2 cells.
Conclusion: The hepatocyte-like cells contained the markers of hepatocytes including CYP450 isotypes. The high
inducibility of CYP450 transcripts could serve as a sensitive model for profiling xenobiotic-induced expression of
CYP450.
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Background
Xenobiotic biotransformation has been classified into 2
phases. The majority of phase I biotransformation was
implemented by cytochrome P450 (CYP450) family with
8 major isotypes in human[1]. Each isotype has over-
lapped spectra of substrates and catalyzes multiple reac-
tions. Activations or suppressions of certain isotypes as
a result of precipitant drugs have been associated with
several clinically important drug interactions[1]. The
phase II biotransformation involved several conjugation
reactions (e.g., sulfonation, glucuronidation, acetylation,
methylation and glutathione conjugation). These
conjugations attach new functional groups to the xeno-
biotic that had gone through phase I metabolism[2].
The CYP450 isotypes in rodents are often different in
gene regulation and enzymatic activity from those in
human and thus cannot reliably predict the toxicity or
metabolic profiles of xenobiotics in human[3].
The idealistic cell culture model to simulate in vivo
biotransformation of xenobiotics is the use of primary
human hepatocytes. However, the acquisition of normal
human hepatocytes is cumbersome with ethical as well
as biological considerations. The cultured cells are short
l i v e da n dh a v et ob es w i f t l yp r e p a r e df r o mf r e s ht i s s u e s
[4] making them unfeasible for most studies. Alternative
sources of human cells have been developed to mimic
the phenotypes of hepatocytes. A viable source is the
mesenchymal stem cells (MSCs) derived from bone
marrow[5].
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was taken through the co-culture of MSCs with isolated
liver cells[6]. Subsequent efforts employed fetal liver-
conditioned medium[7], selective cytokines and coating
matrix[8]. Alternate cell sources such as adipose tissue
[9-11], amniotic fluid[12] and Wharton’s jelly[13-15]
were employed. The major proposed application of
these hepatocyte-like cells is to implement liver regen-
eration[13,16-19]. The xenogeneic transplants of human
hepatocyte-like cells into mice after CCL4-induced liver
injury have been attempted with moderate success
[5,20,21]. Several groups had characterized the pheno-
types (i.e., CYP450, morphology, glycogen/urea/albumin
production) in contemporary hepatocyte-like cells[22],
but none has made the long-term characterization to
demonstrate their stability. The long-term stability of
the cells is required for the application of xenobiotic
testing in new drug development.
The life span of hepatocyte-like cells from these
diverse sources after differentiation induction was gen-
erally limited. Immortalizing hepatocyte-like cells or
their precursors (i.e., MSCs) would be a more feasible
solution, resulting in a sustainable and consistent
source of hepatocytes. The polycomb group transcrip-
tion factor Bmi-1[23] that could drive cancer cell pro-
liferation[24] and normal stem cell self-renewal was
selected for immortalization. The validity for using
these immortalized cells for cell culture metabolic
study relies on the maintenance of hepatocyte pheno-
types as represented by a panel of specific markers.
Hepatocyte-like cells from v a r i o u sM S Cs o u r c e se x h i b -
ited different intensities of hepatocyte specific markers
[9]. We immortalized the MSC as a precursor for
hepatocyte-like cells by using both human telomerase
reverse transcriptase gene (hTERT) and Bmi-1 through
lentiviral transduction[25], and examined whether the
resulting immortalized cells after differentiation induc-
tion could maintain hepatocyte phenotypes and meta-
bolic functions.
Results
The identification of MSCs
Cells isolated from bone marrow aspirate displayed a
spindle shape upon reaching confluence (Figure 1A).
The hTERT/Bmi-1-transduced MSC (BMI1/hTERT-
MSC) still maintained fibroblast-like, spindle morphol-
ogy at 40
th passage (Figure 1B) with an exponential
growth pattern (Figure 1C). The identity of the studied
MSCs was confirmed by the presence of mesenchymal
stem cell markers (CD90 and CD105, Figure 1D). MSCs
that had gone through immortalization still contained
s i m i l a rl e v e l so fC D 9 0a n dC D 1 0 5( F i g u r e1 E ) ,b u tw a s
virtually devoid of hematopoietic markers (CD34, CD45,
Figure 1F) as determined by a flow cytometer.
Proliferative activity of transformed MSCs
The growth rate of MSCs was slow at the first passage,
picked up and steadily increased in subsequent (2
nd-7
th)
passages. In later (8
th -1 0
th) passages, growth rate was
again slowed down to a complete stop (Figure 1C). To
bypass the replication senescence, we transformed
MSCs with either hTERT plus Bmi-1 (BMI/hTERT-
MSC) or hTERT alone (hTERT-MSC) from 5 indepen-
dent donors. After 60 days or 20-25 population doubling
level (PDL), the proliferation rate of untreated MSCs
decreased to a final stop. The cellular morphology
switched to epithelial-like, indicating the reduction of
stem cell properties. In contrast, BMI/hTERT-MSC
grew steadily for more than 8 months (75-80 PDL) and
exhibited unaltered morphology (Figure 1C). In contrast,
hTERT-MSCs, similar to untreated MSCs, could not
bypass replication senescence. BMI/hTERT-MSC cells
have been maintained for over a year, confirming their
immortalization. To ensure that both Bmi-1 and hTERT
were expressed in these transformed MSCs, specific pri-
mers were designed to separately quantify endogenous
and exogenous expression of both Bmi-1 and hTERT
using quantitative RT-PCR. The endogenous expressions
of hTERT and hBmi-1 in untreated MSCs at the 4
th
passage were lower than those in transformed MSCs at
the same passage. The ectopic expressions of both
hTERT and Bmi-1 were detected at a steadily high level
for over a year (120 PDL, Figure 1G). The morphology
was also stable throughout the study. Our success rate
for immortalization of MSC was 4 clones out of 10
clones from each donor.
The differentiation of MSCs to hepatocyte-like cells
After finishing hepatic induction, the hepatocyte-like
cells carried the expansion of several basic hepatocyte
genes (Figure 1H) with a corresponding polygonal mor-
phology (Figure 2A). Immortalized hepatocyte-like cells
at the first passage were loosely attached to adjacent
cells (Figure 2B). Up to 70-80% of the hepatocyte-like
cells deposited glycogen, especially in densely populated
area (PAS assay at passage 4, Figure 2C). After switching
to 10% FBS, DMEM/F12 the intercellular attachment
was denser with blurring of cell boundary (Figure 2D).
At confluence, duct-like structure was observed (Figure
2E). The cells could maintain cell division beyond 3
months (Figure 2F) with sustainable hepatocyte function
suitable for drug screening.
Expression levels of hepatocyte-specific markers
Up to 88% of hepatocyte-like cells (Figure 3A) and
immortalized hepatocyte-like cells (Figure 3B), as
opposed to 5% of MSCs, contained intracellular albu-
min. Almost 95% of HepG2 cells contained albumin
(Figure 3C). In subsequent passages, hepatocyte-like
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Page 2 of 15cells maintained at least 70% of albumin-containing cells
(Figure 3D). The functional activity of hepatocyte-like
cells at different passages was investigated using urea
assay (Figure 3E). The conditioned medium of
hepatocyte-like cells contained far higher level of urea
than that of MSCs, but was comparable to that of
HepG2. Using mRNA levels inherent to MSCs as a
reference, the relative expression levels of the
Figure 1 Characterization of immortalized MSC. MSCs and Bmi-1/hTERT-immortalized MSCs were visualized (A) after the 2
nd passage. The attached
cells appeared fibroblast-like, spindle morphology (B) at the 40
th passage (12 months after isolation). The MSCs (hMSC) and the TERT-transduced MSCs
(hTERT-MSC), or the double TERT/Bmi-1 transduced MSCs (BMI/hTERT-MSC) were studied for cumulative population doubling level (PDL) (C). Flow
cytometry analysis confirmed the presence of CD90/CD105 in primary MSCs after isolation (D) and in BMI/hTERT-MSCs (E). All cells were depleted of
CD35/CD45 hematopoietic stem cell markers (F). The endogenous and exogenous expression of Bmi-1, TERT in all cell types were studied using
quantitative real-time PCR (G). The expression of hepatocyte-selective genes (i.e., albumin (ALB), a-fetoprotein (AFP), cytokeratin18 (CK18), glucose-6-
phosphate dehydrogenase (G6PD), hepatocyte nuclear factor (HNF-4a), and tyrosine aminotransferase (TAT)) of BMI/hTERT-MSC after hepatic
differentiation was presented as fold change over the untreated MSCs in comparison with HepG2 and the primary hepatocyte (H).
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Page 3 of 15Figure 2 Characterization of immortalized MSC-derived hepatocyte-like cells. The TERT/Bmi-1-transduced MSCs had been differentiated
into hepatocyte-like cells. The differentiated cell had polygonal shape, granulated cytoplasm and large nucleus (A). After the next passage, the
cytoplasmic/nucleolus ratio was further decreased with loose intercellular attachment (B). The glycogen storage activity was demonstrated using
Periodic Acid Schiff staining (PAS) with greater than 95% of the population were positive for glycogen (C). After the maintenance in DMEM/F12,
10% FBS in subsequent passages, cells were densely packed with closer intercellular attachment (D). After reaching confluence, cells formed
duct-like structure (E). The life span of the immortalized hepatocyte-like cells was beyond 3 months (F) with active division.
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cells and the primary human hepatocytes were deter-
mined using quantitative real-time PCR. The basal
expression patterns for hepatocyte-specific genes at pas-
sage 5-9 (e.g., ALB, AFP, CK18, G6PD, HNF-4a and
TAT) were varied, depending on the stage of hepatocyte
maturation. The AFP expression that is usually pre-
sented in hepatic progenitors was detected at higher
level than those of the primary human hepatocytes and
HepG2 cells (Figure 1H). The observation of cytokera-
tin18 expression confirmed the differentiation of MSCs
into endodermal tissue. Three major hepatocyte genes
were up-regulated in hepatocyte-like cells, namely glu-
cose-6-phosphate dehydrogenase (glucose metabolism),
HNF-4a (liver development and maturation) and tyro-
sine aminotransferase (amino acid metabolism). The
observation of all hepatocyte specific genes confirmed
that the transformed MSCs could actually differentiate
into functional hepatocyte-like cells.
The basal expression of phase I and phase II enzymes in
hepatocyte-like cell
After maturation induction, hepatocyte-like cell culture
was continued in IMDM with 1% FBS, 2% DMSO for 2
Figure 3 Functional activities of hepatocyte-like cells. The presence of albumin was analyzed using flow cytometer in the immediately
differentiated cells (A), the immortalized hepatocyte-like cells (B), and in HepG2 (C). Greater than 80% of the population of hepatocyte-like cells
contained albumin (D) that could be maintained at 70% beyond 10 passages. Urea production as represented by diacetyl monoxime test was
demonstrated in MSCs, HepG2, and hepatocyte-like cells (E). IMDM medium supplemented with 5 mM NH4Cl served as the control group.
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Page 5 of 15Figure 4 Basal CYP450 activity and its inducibility. The basal expression of CYP450 isotypes, CYP450 nuclear transcription factors, and
UGT1A1 in MSCs, hepatocyte-like cells, HepG2 and the primary hepatocyte were analyzed using real-time qPCR (A). They were analyzed as fold-
changes over that of untreated MSCs. The induction of CYP1A1 (B), CYP1A2 (C), CYP3A4 (D) or CYP2C9 (E) activities after adding the
corresponding enzyme inducers for 72 h were analyzed using P450Glo™ assay kit (Promega) with different luciferin substrates. After 3-h
incubation with specific substrate, luciferase activities were measured. Results are expressed as luciferase activities in relative luminescence unit
(RLU) and mean ± SD of 3 independent experiments.
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determined for phase I and phase II enzyme expressions
(Figure 4A). Specific transcription factors such as AHR,
PXR and CAR in hepatocyte-like cells were increased by
about 10 times those of MSCs. These genes are involved
in the transcription of CYP450 isotypes [27,28]. Genes
that were highly expressed in hepatocyte-like cells
included one phase II enzyme UGT1A1 and 6 CYP450
isotypes (CYP2B6, CYP2D6, CYP2C9, CYP2C19,
CYP3A4, and CYP1A1). In particular, the expression
level of CYP2B6 in hepatocyte-like cells was even higher
than that of HepG2 while other isotypes achieved com-
parable expression levels to those of HepG2. However,
all CYP450 isotype expressions in hepatocyte-like cells
were only 10-20% that of normal hepatocytes. The
authenticity of the real-time RT-PCR products of hepa-
tocyte markers and CYP450 were confirmed through
the analysis for melting curve using Sequence Detection
Software version 2.01 (Applied Biosystems, CA).
Enhancing phase I enzyme expression using prototypic
inducers
The expressions of CYP1A1, CYP2B6, CYP2D6 and
CYP2C8 in hepatocyte-like cells were significantly
i n c r e a s e dt o1 3 ,3 0 ,3 ,1 2f o l d sr e s p e c t i v e l ya f t e rt h e
induction with dexamethasone or rifampicin (Table 1).
CYP3A4 and CYP2C19 expressions were extensively up
regulated by 84 and 20 folds, respectively in hepatocyte-
like cells. In HepG2, the expressions of CYP2B6,
CYP2C8 and CYP3A4 were increased to 25, 9, 39 folds
using rifampicin. In the primary hepatocyte, the expres-
sion of CYP1A1, CYP1A2, CYP2B6 were raised to 19,
13, 41 folds that were comparable to those of the hepa-
tocyte-like cells. The induction of CYP3A4 expression in
the hepatocyte-like cells (84 folds) outpaced that of the
primary hepatocyte (72 folds). The expressions of most
CYP450 isotypes in undifferentiated MSCs were induced
by merely 2-4 folds.
Substantial induction of CYP1A1, CYP1A2, CYP2C9 and
CYP3A4 isotype activities in hepatocyte-like cells
Using luminescent CYP450-specific substrates, we
determined CYP1A1, CYP1A2, CYP2C9 and CYP3A4
isotype activities after the induction with either rifam-
picin or omeprazole in HepG2, MSC and hepatocyte-
like cell. We observed end-point catalytic activity after
incubating substrates to the cells using a luminometer.
In hepatocyte-like cell, the activity of CYP1A1,
CYP1A2 and CYP3A4 was increased to approximately
6-7 folds that of the untreated cell (Figure 4B, C, D).
A mild increase in CYP2C9 activity (2 folds) was
observed (Figure 4E). The activity of CYP1A2 and
CYP3A4 in hepatocyte-like cells was already higher
than those in HepG2. The primary hepatocyte
provided the highest activities in all CYP450 isotypes.
A significant increase in rifampicin-induced CYP3A4
activity was confirmed by the accumulation of CYP450
in hepatocyte-like cell as demonstrated by immuno-
fluorescent staining (Figure 5A). The staining for AFP
and hepatocyte nuclear factor 4a confirmed the iden-
tity of the hepatocyte-like cell. The corresponding
staining to the primary hepatocyte served as the posi-
tive controls (Figure 5B). No significant induction was
detected in untreated MSCs, but untreated HepG2 and
untreated hepatocyte-like cell had low basal level of
CYP1A1, CYP1A2, CYP2C9 and CYP3A4 activities.
Discussion
The hepatocyte-like cells have been developed to replace
the primary hepatocytes for the studies of xenobiotic-
induced CYP450 isotype expression, hepatotoxicity, and
xenobiotic biotransformation. Taken together, the cell
morphology, cell-selective markers (i.e., gene expression
profiles, flow cytometry) as well as certain specific phe-
notypes (urea synthesis, glycogen deposit, and CYP450
expression profiles) indicated that the putative hepato-
cyte-like cells were correctly driven toward hepatocyte
differentiation. To our knowledge, there has not been
any attempt to bring hepatocyte-like cells derived from
MSC as a stable model for the study of CYP450 isotypes
or new drug development. Only certain isotypes
(CYP1A1, CYP1A2, CYP2B6, CYP7A1 and CYP2E1)
have been studied immediately after differentiation
[18,29,30]. The expression of various transcription fac-
tors that regulate CYP450 isotypes[31] including hepato-
cyte nuclear factor (HNF-4a)[ 3 2 ]d u r i n gh e p a t o g e n i c
differentiation has been reported. PXR, AHR and CAR
are considered to be the most important regulators of
xenobiotic-induced regulation of many CYP450 isotypes
[28]. We observed increasing expression of PXR, CAR
and HNF-4a in correlation with the degree of hepato-
cyte-like cell maturation.
Several investigators had developed hepatocyte-like
cells from different stem cell sources and various differ-
entiation protocols[33]. The MSC sources were bone
marrow, adipose tissue and Wharton’s jelly[10,29,34,35].
The differentiation phenotypes were generally lost after
a few days in all studies including one employing
embryonic stem cells as precursors[36]. The senescence
of the precursor MSCs led to decreasing both prolifera-
tion and plasticity [37-39]. Our MSCs also reached
senescence after 20-24 population doublings, similar to
others [40-42]. The generation of hepatocyte-like cells
from MSCs has been plagued by the lack of stable sup-
ply of the precursor MSCs and their differentiation
capacity. These obstacles would be obviated if immorta-
lized hepatocyte-like cells with intact phenotypes could
be generated.
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Page 7 of 15Table 1 Fold changes of CYP450 isotypes’ expression in three cell types after 72 h of induction with prototypic
CYP450 inducers (omeprazole, dexamethasone, rifampicin, artemisinine and ethanol) over the untreated control
P450 isotypes/enzyme inducers concentration (μM) mRNA fold change (mean ± SD)
HepG2 P-hepatocyte hMSC Hep-like cell
CYP1A1
omeprazole 50 4.05 ± 0.38* 11.13 ± 0.34* 2.09 ± 0.30 2.13 ± 0.15
dexamethasone 25 1.11 ± 0.13 19.68 ± 0.46* 3.10 ± 0.33* 12.86 ± 0.39*
CYP1A2
omeprazole 50 3.33 ± 0.14* 6.44 ± 0.80 1.67 ± 0.12 2.37 ± 0.13
dexamethasone 25 1.17 ± 0.02 13.62 ± 2.84* 3.82 ± 0.96* 5.63 ± 0.65*
CYP2B6
rifampicin 40 25.82 ± 1.30* 35.16 ± 2.76** 1.46 ± 0.10 30.70 ± 5.36**
dexamethasone 25 2.58 ± 0.72 41.49 ± 4.58** 3.98 ± 0.71* 24.25 ± 2.30*
CYP2D6
dexamethasone 25 1.26 ± 0.10 5.70 ± 1.29 2.68 ± 0.43 2.90 ± 0.73
CYP2C9
rifampicin 40 1.42 ± 0.25 15.25 ± 2.51* 2.03 ± 0.22 7.78 ± 1.82*
CYP2C19
rifampicin 40 1.87 ± 0.11 29.05 ± 2.02** 2.42 ± 0.61 19.01 ± 2.51*
CYP2C8
rifampicin 40 9.07 ± 1.03* 24.40 ± 2.48* 3.03 ± 0.62* 12.28 ± 0.81*
CYP3A4
rifampicin 40 39.43 ± 5.53** 69.50 ± 6.84** 3.64 ± 1.82* 43.29 ± 3.27**
dexamethasone 25 23.18 ± 7.25** 72.27 ± 5.64** 2.87 ± 0.96 84.10 ± 9.25**
artemisinine 50 48.18 ± 6.80** 59.28 ± 8.41** 0.89 ± 0.07 53.54 ± 1.37**
CYP2E1
ethanol 88 4.59 ± 0.53* 24.23 ± 0.41* 1.46 ± 0.19 10.74 ± 2.10*
hMSC, HepG2, primary hepatocyte and hepatocyte-like cell were induced with prototypic inducer drugs. The CYP450 mRNA level was detected by Real-time PCR.
The experiment was performed in triplicate for all compounds. Data was normalized by untreated (non-treated controls) and was analyzed by Non parametric
One-tailed Student t test (Mann-Whitney test) * p < 0.05, ** p < 0.01.
Figure 5 Immunofluorescent staining of hepatocyte-like cells and the primary hepatocyte. The immunofluorescent staining of CYP3A4, a-
fetoprotein and HNF-4a in the cytoplasm of hepatocyte-like cells (A) and the primary hepatocyte (B) were demonstrated with the
corresponding phase-contrast pictures over the same fields (10× objective lens). Essentially all hepatocyte-like cells carried all 3 proteins but their
staining intensities reached only a half those of the primary hepatocytes.
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telomerase reverse transcript a s e( h T E R T )t h a tp r e v e n t s
replicative senescence associated with decreasing telo-
mere length resulting from repeated cell division
[43,44]. Lesser known immortalization genes are SV-40
large T antigen (T-Ag) and Bmi-1[25]. Bmi-1 inhibit
senescence and extended the life span of normal human
cell by suppressing p16
INK4A that allows cell entry into
division[45]. Moreover, the overexpression of Bmi-1
could inhibit TGF-b signaling[46] that would otherwise
induce hepatocyte cell death[47].
MSCs lost their originally high telomerase activity [48]
after being seeded as primary cultured cells [49] and
eventually lost their stem cell property [50]. We had
expected that the addition of a constitutively expressing
construct of hTERT (pLOX-TERT-iresTK) to MSCs
would solve the senescence [51,52], but a slight post-
ponement of senescence was observed. Only after Bmi-1
(pLOX-CWBmi1)[53] had been co-introduced were the
senescence phenotypes extensively delayed. The trans-
duced cells had increasing spindle morphology with at
least 80% of the whole population contained both CD90
and CD105. These cells could be maintained for over 1
year while still maintaining their growth in exponential
phase. The given constructs have an advantage of the
inclusion of loxP site that allows the removal from the
genomic insertion site.
It is even more exciting when the precursor cells of
the hepatocyte-like cells were already immortalized. We
modified the hepatogenic differentiation protocol from
previous reports [54] by extending the last step of
maturation from 2 weeks to 4 weeks in culture medium
supplemented with 2% DMSO. Normally, we cannot
achieve a complete hepatocyte differentiation. However,
after using limiting dilution technique, a stable clone of
functional hepatocyte-like cell was established. Our
clone of differentiated immortalized cells could propa-
gate in standard culture condition for greater than 6
months with sustainable hepatocyte specific makers and
functions.
The confirmed hepatocyte phenotypes that included
the expression of albumin, a-fetoprotein cytokeratin 18,
HNF-4a, and tyrosine aminotransferase were up-regu-
lated for 10 - 100 folds that of the undifferentiated
MSCs. However, the overall basal gene expressions were
10 - 40% those of the primary hepatocyte. The flow
cytometry analysis indicated that at least 80% of the
hepatocyte-like cells, in comparison with 90% of HepG2,
produced albumin. Likewise, the urea production of our
cells was comparable to that of HepG2. Greater propor-
tion of our hepatocyte-like cells (> 95%) carried glyco-
gen than did others[9,30,55,56]. The expression of
transcription factors for CYP450 (i.e., CAR, AHR, PXR)
as well as that of the phase II enzyme (i.e., UGT1A1)
was observed. The 10 - 50-fold induction of the expres-
sion of 8 major CYP450 isotypes (CYP1A1 CYP1A2,
CYP2B6, CYP2D6, CYP2C9, CYP2C19, CYP2C8,
CYP3A4 and CYP2E1) in response to known enzyme
inducers (rifampicin, dexamethasone, omeprazole, phe-
nobarbital and artesunate) was confirmed, although
their basal levels were less than those of the primary
hepatocyte by 100-1000 folds. Unexpectedly, HepG2
achieved much weaker induction of CYP1A1, CYP2D6,
CYP2C9 and CYP2C19 in response to rifampicin, dexa-
methasone and omeprazole than did hepatocyte-like
cells. The immunofluorescent study of CYP3A4 in hepa-
tocyte-like cells after induction indicated that the up-
regulation of protein level was consistent with the
induction of mRNA expression.
Although CYP450 isotypes are presented in most cell
types, not all cell types are suitably employed to study
the CYP450’s response to xenobiotics. To elucidate the
suitability of the hepatocyte-like cells for the study of
CYP450 isotypes, we have extensively investigated the
e x p r e s s i o n so fa l lm a j o ri s o t y p e sp l u st h ee n z y m a t i c
activity of selected isotypes in response to enzyme indu-
cers. We have demonstrated that the un-modified MSCs
contained low basal levels of CYP450 isotypes and eli-
cited only 2 - 5-fold induction to prototypic CYP450
isotype inducers (Table 1). Therefore, the use of MSCs
is not considered a viable alternative for CYP450 study.
We observed extensively high expressions of most
CYP450 isotypes in response to inducers in hepatocyte-
like cells than those in MSCs or HepG2, although the
basal levels of certain CYP450 isotypes were lower than
those of primary hepatocytes or HepG2. Changing the
precursors of hepatocyte-like cells from MSCs to
embryonic stem cells or induced pleuripotential stem
cells could not bring up the basal levels of all isotypes
[57]. An exception was found in CYP2B6, where the
hepatocyte-like cells had comparable expansion to that
of the HepG2. The low basal levels of these CYP450 iso-
types in hepatocyte-like cells might be attributed to their
completely lack of exposure to xenobiotics as opposed
to the primary hepatocytes or HepG2. Based on the
expansion of CYP450 isotypes’ expression in response to
inducers, hepatocyte-like cells are considered a more
sensitive and informative model.
Conclusion
The continuous hepatocyte-like cell lines have been gen-
erated from hTERT plus Bmi-1-immortalized human
MSCs. These continuous cell lines contained hepatocyte
markers (albumin, AFP, TAT, HNF-4a,G 6 P D )i n c l u d -
ing all major CYP450 isotypes (CYP1A1, CYP1A2,
CYP2C8, CYP2B6, CYP2D6, CYP2C9, CYP2C19,
CYP3A4 and CYP2E1). The basal mRNA expression of
CYP450 isotypes was low, but readily up-regulated up to
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high inducibility of CYP450 transcripts would serve as a
sensitive model for profiling xenobiotic-induced expres-
sion of CYP450.
Methods
The characterization of human mesenchymal stem cells
Human mesenchymal cells (MSCs) were prepared from
aspirated bone marrow of consenting normal volunteers
(n = 5). This study received an approval from the Ethics
Committee on Research Involving Human Subjects at
Ramathibodi Hospital, Mahidol University. Written
inform consent was obtained from all participants
involved in this study. Bone marrow mononuclear cells
were separated by IsoPrep (Robbins Scientific, Canada)
density gradient centrifugation [58] and seeded at a den-
sity of 2 × 10
6 cells/mL in Minimum Essential Medium
(MEM) a Media (Gibco Invitrogen, NY), 10% fetal
bovine serum (FBS, Biochrom AG, Germany), 100 units/
mL penicillin, 100 μg/mL streptomycin at 37°C in 5%
CO2. The identification of MSCs was confirmed using
FACS analysis. Isolated cells were detached by trypsin,
stained for MSC markers (CD105 and CD90) or hema-
topoietic stem cell markers (CD34, CD45), and analyzed
by flow cytometry (FACSCalibur, Becton Dickinson).
Lentivirus production and transduction of target cells
Viral particles were produced using the transient trans-
fection protocol[25]. HEK 293T cells (Clontech, CA) at
a density of 2.8 × 10
6 cells/10-cm tissue culture dish
were co-transfected with psPAX2 packaging vector,
pMD2.G vesicular stomatitis virus G envelope, and the
plasmid encoding either hTERT (pLOX-TERT-iresTK,
Addgene plasmid 12245) or Bmi-1 (pLOX-CWBmi1,
Addgene plasmid 12240)[53] using calcium phosphate
precipitation. The supernatant was harvested and fil-
tered through a 0.45 μm syringe filter. Viral stocks were
stored at -70°C. For immortalization, both hTERT and
Bmi-1 lentiviruses were diluted in MEM a medium,
10% FBS, 6 μg/mL polybrene at a multiplicity of infec-
tion (MOI) of 2, and directly added to the MSCs on six-
well plates (10
4 cells/well). The MSCs were incubated at
5% CO2, 37°C for 14 h. After the incubation, medium
containing viral particles was removed and replaced
with fresh medium.
Cloning of immortalized human mesenchymal stem cell
Three days after the infection, MSCs from 5 donors
were trypsinized and counted using a hemacytometer.
Single cell suspension was prepared by limiting dilution
and transferred onto 24-well culture plate to establish
clones from single cells. Each colony was monitored
every 2-3 d until confluence. The cells were then trypsi-
nized and seeded on T-25 tissue culture flask. To
establish stable MSC lines, 10 clones per donor were
selected based on the fastest cellular proliferation and
confirmed for the expression of both hTERT and Bmi-1.
Total RNA of MSC was isolated from pooled cells of
passages 3-5, converted into cDNA and quantitated
using real-time PCR. hTERT and Bmi-1 double positive
cells were studied for population doubling level (PDL).
The population doubling level was determined using log
N/log2, where N is the number of the cells harvested at
confluence divided by the number of the initially seeded
cells [25].
The induction of MSC hepatogenesis
The MSCs at passages 3-5 or BMI/hTERT-MSCs at a
d e n s i t yo f1×1 0
4 cells/cm
2 from the fastest dividing
clone (n = 3) were taken for differentiation. The MSCs
were induced into hepatocyte-like cells using a modified
three-step protocol[9]. They were maintained on col-
lagen type IV coated container. The cells were main-
tained for 2 d in serum-free IMDM (Gibco Invitrogen,
NY), 20 ng/mL epidermal growth factor (EGF, Chemi-
con, CA),10 ng/mL basic fibroblast growth factor (bFGF,
Chemicon, CA). Cells were then maintained in IMDM
(20 ng/mL HGF, Chemicon, CA), 10 ng/mL bFGF, and
0.61 g/L nicotinamide (Sigma, MO) for 7 d. Cells were
further maintained in IMDM, 20 mg/mL oncostatin M
(OSM, Chemicon, CA), 1 μM dexamethasone (Sigma,
MO), and 50 mg/mL ITS
+ (Gibco Invitrogen, NY) for
14 d. The hepatogenesis was assessed by real-time PCR
for liver-associated genes. Both human hepatocellular
carcinoma cell line (HepG2) and the primary human
hepatocyte served as controls. HepG2 was maintained in
DMEM/F12 (Gibco Invitrogen, NY), 10% FBS, 100
units/mL penicillin (Sigma, MO), and 100 μg/mL strep-
t o m y c i n( S i g m a ,M O )a t3 7 ° Ci n5 %C O 2. The primary
human hepatocyte was maintained in Williams media E
(Gibco Invitrogen, NY), 10% FBS, 100 units/mL penicil-
lin (Sigma, MO), 100 μg/mL streptomycin (Sigma, MO),
4 μg/mL insulin and 1 μM dexamethasone (Sigma, MO)
at 37°C in 5% CO2.
Urea production assay
MSCs, hepatocyte-like cells at passages 0-10 and HepG2
(HB-8065, ATCC, USA) were stimulated with 5 mM
NH4Cl (Sigma, MO) for 48 h. The culture medium was
collected and assayed for urea using diacetyl monoxime
test[59]. The resulting diazine was measured at 540 nm
with the SpectraMax M5 spectrofluorometer (Molecular
Devices, CA).
Glycogen Synthesis (Periodic Acid-Schiff, PAS) Assay
Immortalized hepatocyte-like cells at passage 4 were
cultured on a chambered slide (Lab-Tek, Nunc, Den-
mark) for 3d. The slides were fixed in 4% formaldehyde,
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bated with or without diastase for 1 h at 37°C, oxidized
in 1% periodic acid (Sigma, MO) for 5 min, rinsed thrice
with dH2O, treated with PAS reagent (Sigma, MO) for
15 min, and rinsed with water for 5 - 10 min. Samples
were counterstained with Mayer’s hematoxylin for 1
min, rinsed with water, and assessed under light micro-
scope. The resulting gradient of oxidized glycogen
would yield a gradient of color starting from pink to
strong red.
Analysis of cellular markers using flow cytometry
The cultured cells were stained with fluorochrome-con-
jugated to primary monoclonal antibodies raised against
MSC markers (CD90, CD105); hematopoietic markers
(CD34, CD45) (Biosource Invitrogen, CA). For intracel-
lular albumin accumulation, hepatocyte-like cells at pas-
sages 2-10 were incubated with FACS Perm (BD
Bioscience, CA) and stained with anti-human albumin
(Abcam, MA). The goat anti-mouse IgG conjugated to
FITC (Santa Cruz Biotechnology, CA) was used as the
secondary antibody as necessary. The labeled cells were
quantitated using a FACSCalibur flow cytometer (BD
Bioscience). The data were analyzed using WinMDI ver-
sion 2.9.
Immunofluorescence Microscopy
Hepatocyte-like cells and the primary hepatocytes on
chambered slide were washed twice with PBS, fixed with
4% paraformaldehyde for 30 min at room temperature
followed by 100% ethanol for 10 min. The fixed cells
were washed thrice with PBS, blocked with 5% normal
serum from the same species as the secondary antibody
in 1% BSA/0.2% Triton X-100/PBS for 1 h at room tem-
perature. The cells were incubated with the primary
antibody (anti-CYP3A4, anti-HNF4 or anti-a1-fetopro-
tein; Abcam, MA) for 1 h at 37°C, washed thrice, incu-
bated with the secondary antibody for 1 h at 37°C,
washed thrice, mounted with anti-fade mounting med-
ium on coverslip, and examined under a fluorescent
microscope.
The induction of major CYP450 isotypes in hepatocyte-
like cells using selective enzyme inducers
The modulation of expression levels of CYP450 isotypes
was studied after the exposure to the classical inducers
[1,22,60,61]. HepG2, MSC or hepatocyte like-cell from
passages 3-7 at sub-confluent density were seeded on 6
well-plates for 48 h. These cells were treated for 72 h
with the following agents: 40 μM rifampicin, 25 μM
dexamethasone, 50 μM omeprazole, 1 mM phenobarbi-
tal, 50 μM artesunate, 88 μM ethanol or 0.1% (v/v)
DMSO. The cell pellets were washed with 2-3 mL PBS,
detached using 0.025% trypsin-EDTA, and neutralized
with 10% FBS in IMDM. The cell pellets from passages
3-7 were pooled and stored at -80°C until analysis for
CYP450 gene expression.
Cell isolation, extraction of total mRNA and production of
cDNA from primary hepatocyte, hepatocyte-like cell,
MSCs and HepG2
The primary human hepatocytes were prepared from
discarded surgical specimens using the 2-step collage-
nase method. The isolated cells were seeded over the
collagen type IV-coated container and maintained in the
above growth medium for 3 days. Total RNA isolation
was performed using RNeasy Mini kit (Qiagen, Ger-
many) according to the manufacturer’s instruction. The
quality and quantity of the total RNA were determined
using a NanoVue Spectrophotometer (GE Healthcare,
Buckinghamshire, UK). For cDNA synthesis, 2 μgo f
total isolated RNA from primary hepatocyte, hepato-
cyte-like cell, HepG2 and hMSC were converted to
cDNA using the ImProm-II reverse transcription system
( P r o m e g a ,W I ) .B r i e f l y ,i s o l a t e dR N Aw a si n c u b a t e d
with 0.5 μgo l i g o( d T ) 15 primer in a total volume of 5
μL at 70°C for 5 min and chilled on ice-water immedi-
ately for at least 5 min. The reverse transcription mix
(15 μL of 5X reaction buffer, 25 mM MgCl2,2m M
dNTP Mix, 40 U/μL RNasin ribonuclease inhibitor, and
200 U/μL Improm-II
™ R T )w a sa d d e dt ot h eR N A - p r i -
mer mix to make a total volume of 20 μL. The mixture
was incubated at 25°C for 5 min, and 42°C for another 1
h. The RT reaction was terminated by heating at 70°C
for 15 min followed by chilling on ice. The cDNA sam-
ples were either used immediately or stored at -70°C.
The 1.2 kb kanamycin RNA (1 μg) and non-template
control served as positive and negative control system.
Quantitative real-time PCR analysis for cell-specific
markers
The employed hepatocyte markers included: ALB (albu-
min), AFP (a-fetoprotein), CK18 (cytokeratin18), G6PD
(glucose-6-phosphate dehydrogenase), HNF-4a (hepato-
cyte nuclear factor 4a), and TAT (tyrosine amino trans-
ferase). The employed CYP450 markers included
CYP1A1, CYP1A2, CYP2C8, CYP2B6, CYP2D6,
CYP2C9, CYP2C19, CYP3A4 and CYP2E1. The primers
for assessing P450s included those recognized aromatic
hydrocarbon receptor (AHR), pregnane × receptor
(PXR), constitutive aldosterone receptor (CAR). All gene
specific primers were designed using Vector NTI version
10 (Invitrogen, Table 2) and ordered from 1st BASE
(Singapore). They were amplified using FastStart SYBR
®
Green Master (Roche diagnostic) and an ABI 7500
Sequence Detector (Applied Biosystems, CA) by follow-
ing checklist information of RT-qPCR experiment
(Additional file 1). Real-time PCR was performed using
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mixture containing 0.4 μM for each primer and 12.5 μL
SybrGreen with the following conditions: 95°C for 10
min, followed by 40 cycles of amplification at 95°C for
15 sec, 60°C for 40 sec, and 72°C for 40 sec. The fluor-
escent products were measured at the last step of each
cycle. To determine the specificity of amplification,
melting curve analysis was applied to all final PCR pro-
ducts, after finishing the thermal cycling. The non-
template negative control (NTC) was performed with
each gene-specific primer pair. The number of cycles
required for the fluorescent signal to cross the threshold
(Ct’s) was determined from each primer pair. The
obtained Ct’s were subtracted with the Ct of the respec-
tive house-keeping gene (GAPDH) of the same cells to
obtain ΔCt. To enable suitable comparison, the ΔCt’so f
the treated cells were subtracted with ΔCt’so ft h e
untreated cells of the same period to obtain ΔΔCt’s.
Table 2 Primer sets and conditions used in quantitative real-time PCR (qPCR)
Gene Genbank
Accession
Sense primer
5’——— >3 ’ (Tm°C)
Antisense primer
3’——— >5 ’ (Tm°C)
Size
amplicon
(bp)
Annealing
temp. (°C)
Putative function
ALB NM_000477 TGAGAAAACGCCAGTAAGTGAC
(60.8)
TGCGAAATCATCCATAACAGC
(58.7)
265 60 albumin
AFP NM_001134 GCTTGGTGGTGGATGAAACA (60.4) TCCTCTGTTATTTGTGGCTTTTG
(59.2)
157 60 a-fetoprotein
CK18 X12881 GAGATCGAGGCTCTCAAGGA (62.4) CAAGCTGGCCTTCAGATTTC (60.4) 357 60 cytokeration 18
G6PD U01120 GCTGGAGTCCTGTCAGGCATTGC
(68.1)
TAGAGCTGAGGCGGAATGGGAG
(66.4)
349 60 glucose-6-phosphate
dehydrogenase
HNF-4a AY680696 GCCTACCTCAAAGCCATCAT (60.4) GACCCTCCCAGCAGCATCTC (66.5) 256 60 hepatocyte nuclear
factor 4a
TAT NM_000353 TGAGCAGTCTGTCCACTGCCT (64.5) ATGTGAATGAGGAGGATCTGAG
(60.8)
338 60 tyrosine aminotransferase
CYP2B6 NM_000767 ATGGGGCACTGAAAAAGACTGA
(60.8)
AGAGGCGGGGACACTGAATGAC
(66.4)
283 60 Cytochrome P450 2B6
CYP2D6 NM_000106 CTAAGGGAACGACACTCATCAC
(62.7)
GTCACCAGGAAAGCAAAGACAC
(62.7)
289 60 Cytochrome P450 2D6
CYP2C9 NM_000771 CCTCTGGGGCATTATCCATC (62.4) ATATTTGCACAGTGAAACATAGGA
(57.7)
137 60 Cytochrome P450 2C9
CYP2C19 NM_000769 TTCATGCCTTTCTCAGCAGG (60.4) ACAGATAGTGAAATTTGGAC (54.3) 277 60 Cytochrome P450 2C19
CYP2C8 NM_000770 ACAACAAGCACCACTCTGAGATATG GTCTGCCAATTACATGATCAATCTCT 100 60 Cytochrome P450 2C8
CYP3A4 AK298451 GCCTGGTGCTCCTCTATCTA (62.4) GGCTGTTGACCATCATAAAAGC
(60.8)
187 60 Cytochrome P450 3A4
CYP1A1 BC023019 TCCAGAGACAACAGGTAAAACA
(58.9)
AGGAAGGGCAGAGGAATGTGAT
(62.7)
371 60 Cytochrome P450 1A1
CYP1A2 AF182274 ACCCCAGCTGCCCTACTTG (64.5) GCGTTGTGTCCCTTGTTGT (62.4) 101 60 Cytochrome P450 1A2
CYP2E1 NM_000773 ACCTGCCCCATGAAGCAACC (64.5) GAAACAACTCCATGCGAGCC (62.4) 246 60 Cytochrome P450 2E1
PXR AB307701 GAAGTCGGAGGTCCCCAAA (62.3) CTCCTGAAAAAGCCCTTGCA (60.4) 100 60 pregnane × receptor
CAR AB307702 TGATCAGCTGCAAGAGGAGA (60.4) AGGCCTAGCAACTTCGCACA (62.4) 102 60 constitutive androstane
receptor
AhR BC070080 ACATCACCTACGCCAGTCGC (64.5) TCTATGCCGCTTGGAAGGAT (60.4) 101 60 aryl hydrocarbon
receptor
UGT1A1 BC128414 GGAGCAAAAGGCGCCATGGC
(62.5)
GTCCCCTCTGCTGCAGCTGC (64.5) 178 60 uridine diphosphate
glucuronyltransferase
1A1
LV-BMI-
1
NM_005180 GCTGAGGGCTATTGAGGCGCA
(65.5)
ACCCCAAATCCCCAGGAGCTGT
(65.7)
127 60 lentivirus vector BMI-1
hBMI-1 NM_005180 ACCTCCCAGCCCCGCAGAAT (65.9) AGACGCCGCTGTCAATGGGC (66.4) 280 60 human BMI-1
LV-
hTERT
AF018167 CAACCCGGCACTGCCCTCAG (66.9) GGGGTTCCGCTGCCTGCAAA (68.2) 268 60 lentivirus vector
telomerase reverse
transcriptase
hTERT AF018167 CGGAAGAGTGTCTGGAGCAAGT
(59.5)
GAACAGTGCCTTCACCCTCGA
(61.1)
258 60 human telomerase
reverse transcriptase
Sequence of the primers and the conditions used in quantitative real-time PCR (qPCR).
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expression of 2
-(ΔΔCt).
The analysis of CYP450 activity
CYP1A1, CYP1A2, CYP2C9 and CYP3A4 enzyme activ-
ities were assayed directly in all cultured cells (immorta-
lized hepatocyte-like cell at passage 3-7, primary human
hepatocyte, HepG2 or MSC) attaching to the collagen
type IV-coated 6-well plate at a density of 10
6 cell/well.
All cultured cells were divided into three groups. Group
1: cells were cultured in IMDM supplemented with 40
μM rifampicin to induce CYP450 isotypes 3A4 and 2C9.
Group 2: cells were cultured in IMDM supplemented
with 50 μM omeprazole for inducing CYP1A1 and
CYP1A2. Group 3: cells were cultured in IMDM alone
as a control. All conditions were incubated for 72 h
with daily medium change. Metabolism was assessed
based on luciferase activityu s i n gt h eP 4 5 0 - g l o1 A 1 ,
1A2, 2C9 and 3A4 assay (V8751, V8771, V8791, V9001;
Promega, WI). After 3-d incubation period, cells were
incubated with IMDM supplemented with 100 μM Luci-
ferin-CEE, Luciferin-H, Luciferin-ME for 3-4 h or 3 μM
Luciferin-IPA for 30-60 min. An aliquot (50 μL) of the
medium was transferred to 96-well opaque white lumin-
ometer plate (Nunc, Denmark) and luciferin detection
reagent was added to each well. After sitting at room
temperature for 20 min, luminescence was measured
with a SpectraMax M5 spectrofluorometer.
Statistical analysis
Each experiment was performed in triplicate. Data were
expressed as mean ± SD. Data from quantitative RT-
qPCR and enzyme activity were evaluated for statistical
significance using the Student’su n p a i r e dt test (p <
0.05). At least 3-fold induction in mRNA with statisti-
cally significant difference was judged as relevant.
Additional material
Additional file 1: Details of quantitative RT-PCR conditions. This file
contains the tabulated specific information for qRT-PCR section.
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